Hydroxychloroquine denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for hydroxychloroquine are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Hydroxychloroquine as "Not FDA-Approved" — and How to Appeal

Hydroxychloroquine (HCQ) holds FDA approval for specific indications including systemic lupus erythematosus (SLE), discoid lupus, and malaria prophylaxis and treatment. When Humana issues a "not FDA-approved" denial, it almost always means one of two things: the claim was submitted under a diagnosis code that does not align with an FDA-labeled indication, or the plan is treating a particular use as off-label without considering applicable medical literature and guidelines.

This denial is absolutely worth appealing. If your physician is prescribing HCQ for a recognized, labeled indication, the denial is likely a coding or administrative error that can be corrected quickly. If use is off-label, the appeal path requires demonstrating that the use is supported by recognized compendia (such as those referenced under Medicare's compendia standards) and applicable specialty society guidance — for instance from the American College of Rheumatology.

## Your Federal Appeal Rights

• Internal appeal: ERISA §503 and ACA §2719 require Humana to provide a full-and-fair internal review. Request this in writing within the timeframe shown on your denial letter (typically 180 days).
• External review: After exhausting internal appeals, you have access to an Independent Review Organization (IRO) under ACA §2719 external review provisions. You generally have four months (180 days) from the denial to initiate external review.
• Expedited review: If your condition is urgent, request expedited internal and external review simultaneously. Humana must respond to an expedited internal appeal within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation — chart notes, lab results, or specialist letters confirming the specific diagnosis (e.g., SLE, discoid lupus) with corresponding ICD-10 code. 2. Prescriber medical-necessity letter — a detailed letter from your rheumatologist or treating physician explaining the diagnosis, why HCQ is indicated, and referencing the applicable guideline organization (e.g., ACR guidelines) without relying on numbers alone. 3. Prior treatment history — dates, doses, and outcomes of any alternative treatments tried, particularly if step-therapy was also a factor. 4. FDA prescribing information — reference the current FDA-approved label to establish the on-label indications and confirm your use aligns. 5. Humana's coverage policy — request a copy of Humana's current medical/drug policy for HCQ so your appeal addresses each listed criterion.

## Criteria-Mapping Structure

Build your appeal letter as a table or numbered list. For each criterion in Humana's policy, state the criterion verbatim, then cite the exact chart fact that satisfies it (e.g., "Criterion: diagnosis of SLE — Met: rheumatologist confirmation dated [date], ICD-10 code M32.x documented in chart"). This structure forces the reviewer to address each point individually rather than issuing a blanket denial.